Assistance Publique - Hôpitaux de Paris: Melanoma trials

The registry lists 14 Melanoma studies with Assistance Publique - Hôpitaux de Paris as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 4No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic MelanomaRecruitingNCT06774989
• Immune Profiles Evolution Under Immunotherapy for MelanomaRecruitingNCT04576429Not applicable
• Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target?Not yet recruitingNCT04477876
• Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable PrimaryRecruitingNCT02828202
• Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of RecurrenceStatus unknownNCT05062096Not applicable
• Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOmaCompletedNCT04988841Phase 2
• Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint InhibitorsCompletedNCT04253080Not applicable
• Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With MelanomaStatus unknownNCT04021420Phase 1/2
• Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced MelanomaStatus unknownNCT02938728
• Tracing Dissemination of Melanoma Cells in Healthy TissuesCompletedNCT02854124
• Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic MelanomaStatus unknownNCT02202200Phase 1/2
• Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma PatientsCompletedNCT01336270
• Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.Status unknownNCT01168050Phase 2
• Multicentric Cohort of Melanoma Patients in Ile de France AreaCompletedNCT00839410